In addition, studies have shown that the inhibitor Sotorasib directly targets the KRAS G12C mutant protein, thereby improving survival in patients with KRAS G12C mutations in NSCLC (180). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.